Addario Lung Cancer Medical Institute - ALCMI

Addario Lung Cancer Medical Institute - ALCMI We fund and support investigator-led lung cancer clinical trials.

Oregon State University researchers have made a compelling dual-target discovery. They have developed a single therapy t...
04/18/2026

Oregon State University researchers have made a compelling dual-target discovery. They have developed a single therapy that simultaneously targets lung cancer and cancer cachexia.

PORTLAND, Ore. – Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it. The study, published in the Journal of Controlled Release, involves lipid nanoparticles delivering therapeuti...

EGFR-mutated NSCLC is not just another subtype of lung cancer — it is a distinct molecular entity that demands a fundame...
04/17/2026

EGFR-mutated NSCLC is not just another subtype of lung cancer — it is a distinct molecular entity that demands a fundamentally different treatment strategy.

In this segment, Alexander Spira, MD, PhD, engages Natalie Vokes, MD, in a discussion on the distinct biology of EGFR-mutated non–small cell lung cancer and how it informs treatment decisions in the early-stage setting.

Wow! Researchers at Roswell Park Comprehensive Cancer Center and Winship Cancer Institute of Emory University have devel...
04/16/2026

Wow! Researchers at Roswell Park Comprehensive Cancer Center and Winship Cancer Institute of Emory University have developed an AI-powered pathology tool that can predict treatment response in extensive-stage small cell lung cancer before a single dose of chemotherapy is given.

Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy—before treatment has begun, and without additional biopsies. That means patients can avoid ...

New research is challenging the idea of how old is too old for surgery in early-stage lung cancer.
04/15/2026

New research is challenging the idea of how old is too old for surgery in early-stage lung cancer.

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have found that adults aged 80 and older with early-stage lung cancer can safely undergo surgery and achieve outcomes comparable to younger patients, challenging longstanding assumptions about age a...

04/14/2026

Congrats to the researchers at the ALCMI consortium member, Mass General Brigham Cancer Institute. They have shown that pralsetinib can extend median overall survival for advanced RET fusion-positive NSCLC from roughly 4–11 months to 44 months.

Mass General Brigham Cancer Institute study found that patients with advanced RET fusion-positive lung cancer showed robust and durable responses.

Congrats to TRIANA Biomedicines! The company has earned FDA Fast Track designation for TRI-611, a first-in-class molecul...
04/13/2026

Congrats to TRIANA Biomedicines! The company has earned FDA Fast Track designation for TRI-611, a first-in-class molecular glue degrader targeting ALK fusion proteins in ALK-positive non-small cell lung cancer.

Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1/2 trial.

New trial alert! Memorial Sloan Kettering Cancer Center has launched a new investigator-initiated Phase 2 trial evaluati...
04/12/2026

New trial alert! Memorial Sloan Kettering Cancer Center has launched a new investigator-initiated Phase 2 trial evaluating BIO 300 Oral Suspension in patients with non-small cell lung cancer and concomitant interstitial lung disease.

MINNEAPOLIS, March 31, 2026--Investigator-initiated at a leading cancer center will provide explore BIO 300's potential.

A new study found that incidental findings flagged during low-dose CT screening could be signs of other non-lung, undiag...
04/11/2026

A new study found that incidental findings flagged during low-dose CT screening could be signs of other non-lung, undiagnosed cancers.

This cohort study examines the association between significant incidental findings on lung cancer screening in the National Lung Screening Trial and the diagnosis of an extrapulmonary cancer within 1 year of the screen.

Congratulations to Anurag Singh, MD, and the team at Roswell Park Comprehensive Cancer Center on a finding that could re...
04/10/2026

Congratulations to Anurag Singh, MD, and the team at Roswell Park Comprehensive Cancer Center on a finding that could reshape how we treat early-stage non-small cell lung cancer.

A study by Dr. Singh confirms shorter, lower doses of radiation are effective against lung cancer

In a recent OncLive discussion, Dr. Lovly and Dr. Lee examined how risk-benefit profiles should drive frontline treatmen...
04/09/2026

In a recent OncLive discussion, Dr. Lovly and Dr. Lee examined how risk-benefit profiles should drive frontline treatment selection, weighing efficacy, toxicity, and patient-specific factors when choosing between osimertinib monotherapy and combination approaches such as amivantamab-vmjw plus lazertinib.

Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how data help shape first-line treatment decisions in EGFR-mutated non–small cell lung cancer.

Updated data from the phase 2 PALOMA-2 trial point to a meaningful advance in first-line treatment for patients with EGF...
04/08/2026

Updated data from the phase 2 PALOMA-2 trial point to a meaningful advance in first-line treatment for patients with EGFR-mutated metastatic NSCLC.

Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.

Fascinating! Researchers have identified that lung cells age at different rates, with implications for lung cancer risk ...
03/27/2026

Fascinating! Researchers have identified that lung cells age at different rates, with implications for lung cancer risk and targeted therapies.

There are many serious health conditions and diseases that are associated with aging, like pneumonia, as well as lung cancer and COPD ... | Cell And Molecular Biology

Address

1100 Industrial Road, Suite 1
San Carlos, CA
94070

Telephone

+16505982857

Website

Alerts

Be the first to know and let us send you an email when Addario Lung Cancer Medical Institute - ALCMI posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Addario Lung Cancer Medical Institute - ALCMI:

Shortcuts

Share

Category